Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and ...
Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...
Esperion (ESPR) has filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications ...
If you have high cholesterol, your doctor may prescribe you with a type of statin. Here’s what you need to know. Statins are a group of medications used to treat high cholesterol. They work by ...
A UCLA study has outlined a new framework that researchers say would improve the predictive power of genetics to determine ...
a class of drug that effectively reduces cholesterol. Guidelines for doctors do not recommend prescribing statins to diabetic patients unless they have high cholesterol levels. But the new ...
Overall, a 20% decrease in LDL cholesterol was seen. Participants reported that they would have found more information on drug interactions ... make statins unavailable to non-insured or indigent ...
has submitted New Drug Submissions to Health Canada for two cholesterol-lowering medications, NEXLETOL and NEXLIZET, the company announced today. These oral, non-statin drugs are designed to ...
The patient asked: "I have high cholesterol, but when I tried statins, I didn't like the side effects. What are non-pharmaceutical ways ... to the impact of older statin drugs from the '90s.
ANN ARBOR, Mich. - Esperion (NASDAQ: NASDAQ:ESPR), which has seen remarkable revenue growth of 187% over the last twelve months, has submitted New Drug Submissions to Health Canada for two cholesterol ...
Excess cholesterol is known to form artery-clogging plaques that can lead to stroke ... With the spotlight on SPT, the team ...